Thinking of joining a study?

Register your interest

NCT06348173 | COMPLETED | Asthma


Response and Remission to Treatment With Anti-IL5/IL5R Antagonists
Sponsor:

University of Montreal

Brief Summary:

The aim of this retrospective observational study is to compare the response and remission rate after treatment with IL5/IL5-R antagonists in asthmatics who would and would have not met the inclusion criteria of the original randomized clinical trials. This study will be performed using the charts of the patients.

Condition or disease

Asthma

Intervention/treatment

Mepolizumab

Detailed Description:

Objective To compare the response and remission rate after treatment with IL5/IL5-R antagonists in asthmatics who would and would have not met the inclusion criteria of the original RCTs. After having obtained authorization from the ethics committee of the CIUSSS du nord de l'île de Montréal and from the director of the Professional Services, all the charts of patients who received anti IL5/IL-5R at the tertiary asthma clinic of the Hôpital du Sacré-Coeur de Montréal will be reviewed. Patients aged 75 years or younger, with a smoking history of less than 10 pack-year, and a FEV1 \<80% predicted with reversibility in the previous year will be considered to fulfill the RCTs criteria. Response to treatment was defined by at least a 50% reduction in asthma exacerbations or in oral corticosteroids (OCS) doses in the year following the initiation of IL5/IL5R antagonists. Clinical remission on treatment at one year was defined as no exacerbation, no OCS and la 10% or less decrease in pre-bronchodilator FEV1 compared with baseline value.

Study Type : OBSERVATIONAL
Estimated Enrollment : 109 participants
Official Title : Response and Remission to Treatment With Anti-IL5/IL5R Antagonists in a Real-world Setting
Actual Study Start Date : 2023-06-01
Estimated Primary Completion Date : 2023-11-30
Estimated Study Completion Date : 2023-11-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Criteria
Inclusion Criteria
  • Patients 18 years and older who were followed at the outpatient asthma clinic of Sacre-Cœur Hospital and have been treated with anti-IL5/il5R between 2016 and 2020.
Exclusion Criteria
  • None

Response and Remission to Treatment With Anti-IL5/IL5R Antagonists

Location Details

NCT06348173


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

Canada, Quebec

Montreal Sacred Heart-Coeur Hospital

Montréal, Quebec, Canada, H4J 1C5

Loading...